Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

Guyman567 has been using oral finasteride and topical minoxidil for years but continues to experience hair loss and thinning, which has affected his confidence. He has tried various treatments including topical finasteride, microneedling, and vitamins, and is considering a hair transplant but is concerned about ongoing hair loss.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.

A 26-year-old male considering a hair transplant is using topical finasteride and minoxidil, planning to start feminizing hormone replacement therapy (HRT) with estrogen and spironolactone. Many suggest waiting to see the effects of HRT, which may significantly regrow hair, before deciding on a transplant, and recommend adding microneedling and possibly switching to oral treatments for better results.

Skepticism about hair loss research motivations, suggesting financial interests hinder finding a cure. Mentions treatments like minoxidil, finasteride, and dutasteride, but notes they are not cures.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

The conversation humorously suggests that drug use might be more effective for hair retention than traditional treatments like minoxidil or finasteride. It attributes full heads of hair in homeless individuals to lifestyle factors like reduced stress or hormonal changes.

A user stopped finasteride after 15 years due to severe side effects, which improved after quitting. They maintained most of their hair and are considering alternatives like topical treatments or RU58841.

PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.

Being overweight may increase finasteride side effects due to higher aromatase activity converting testosterone to estradiol. Maintaining a healthy weight could reduce these side effects.

A doctor advised against using finasteride or dutasteride during pregnancy. The user continues with oral and topical minoxidil, microneedling, tretinoin, Nizoral, and pyrilutamide.

The conversation discusses why the difference between donor and balding hair isn't studied more to find a cure for hair loss. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The post discusses a user's experience with hair loss treatments, specifically topical finasteride, minoxidil, and micro-needling, and their plan to switch to oral versions and add Dutasteride. The conversation includes various responses, with some users sharing their own experiences and side effects, and others expressing desire for a more permanent hair loss solution.

Most hair loss treatments are ineffective; only finasteride, dutasteride, and minoxidil show effectiveness.

Many people experience hair loss but don't treat it. Common treatments include Minoxidil, Finasteride, and microneedling.

The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

Finasteride and dutasteride are discussed as preventative treatments for hair loss, with some advocating for early use and others concerned about side effects, especially before full maturity. Many regret not starting these treatments earlier due to their effectiveness in preventing or slowing hair loss.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

A user shared their successful hair regrowth journey using oral minoxidil, dutasteride, and eucapil, with additional benefits from MTF hormone replacement therapy. They advised consulting specialists and considering individual responses to treatments.

Stemson Therapeutics has shut down, disappointing those seeking a hair loss cure. Current treatments like minoxidil, finasteride, and dutasteride are discussed, with some users experiencing side effects and exploring alternatives like PP405.

The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hair follicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.

A user added sandalore to minoxidil for hair loss, observing some vellus hair growth and less scalp inflammation. Others tried sandalore with mixed results, discussing dosage and effectiveness compared to minoxidil and finasteride.

CraigMeyerShirtPants used oral finasteride for 15 months and topical minoxidil for 6 months, seeing significant hair growth after cutting hair 4 months ago. Users congratulated and asked about age, brand, and side effects.